[18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial
Open Access
- 28 October 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (4) , 2217-2233
Abstract
Purpose Ultra-short immunotherapy may spare cutaneous squamous cell carcinoma (CSCC) patients from mutilating surgery, but early identification of (non-)response is needed to safely guide treatment adaptation. This study evaluated the feasibility of sequential [18F]FDG-PET/CT (FDG-PET) as a response biomarker in resectable CSCC patients. Methods In the MATISSE, a randomized phase-II trial, 50 CSCC patients received two courses of neoadjuvant nivolumab (weeks 0 and 2) with or without low-dose ipilimumab (week 0) before surgery (week 4). FDG-PET scans were obtained pre-treatment and shortly prior to surgery to assess the change (Δ) in maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) at the primary tumour and largest (= index) lymph node metastasis (ILN). ΔMTV50%/4.0 and ΔTLG50%/4.0 were calculated using thresholds of 50% SUVmax and SUV ≥ 4.0. Results In 42 evaluable patients, 31 (74%) patients showed major or partial responses to immunotherapy. EORTC-criteria underestimated response but accurately identified non-responders (70% sensitivity, 100% specificity). In 28 primary tumours and 22 ILNs, a significant reduction in median SUVmax, MTV50%, MTV4.0, TLG50%, and TLG4.0 was observed in responders versus non-responders (overall, p ≤ 0.004, and p ≤ 0.03, respectively). ΔTLG50% and ΔTLG4.0 correlated strongly with response (primary: 92% and 96% accuracy; ILN: 91% and 89% accuracy). Conclusions Quantitative FDG-PET-response assessment allows early identification of (non-)responders upon neoadjuvant immunotherapy prior to surgery in locoregionally advanced CSCC patients. Early changes in FDG-PET’s TLG can support future trials aiming at safe de-escalation of current standard of care surgery with or without adjuvant radiotherapy. Trial registration: EudraCT 2020–001074-30. Registered 9 March 2020, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001074-30Keywords
Funding Information
- Bristol Myers Squibb Foundation (CA209-7W9)
- Riki Foundation
This publication has 34 references indexed in Scilit:
- Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaJAMA Surgery, 2022
- [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Epidemiology of Skin Cancer: Update 20192020
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJAMA Oncology, 2020
- The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Cutaneous squamous cell carcinomaJournal of the American Academy of Dermatology, 2018
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012JAMA Dermatology, 2015
- Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: Rapid incidence increase among young Danish womenInternational Journal of Cancer, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009